Assessing the Safety and Benefit of Home-hospitalization Program in the Management of Natalizumab (Tysabri®) Medication in Multiple Sclerosis
Latest Information Update: 21 Mar 2024
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms Tys at Home
- 18 Mar 2024 Planned End Date changed from 1 Jun 2024 to 15 May 2025.
- 18 Mar 2024 Planned primary completion date changed from 1 Mar 2024 to 15 Nov 2024.
- 18 Mar 2024 Status changed from recruiting to active, no longer recruiting.